Trial Profile
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis: a Randomised Placebo-controlled Double Masked Parallel Trial (TRACKER)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nomacopan (Primary)
- Indications Keratoconjunctivitis
- Focus Adverse reactions
- Acronyms TRACKER
- Sponsors Akari Therapeutics
- 16 Mar 2021 Status changed from active, no longer recruiting to terminated early due to the disruptions caused by the ongoing COVID-19 pandemic. The decision was not related to any efficacy, safety or clinical concerns regarding rVA576/Coversin.
- 11 Mar 2021 This trial has been discontinued in Spain, according to European Clinical Trials Database record. (Global end date: 2020-12-15)
- 03 Nov 2020 Status changed from suspended to active, no longer recruiting.